跳到正文
11月7日周六
11月6日周五
  1. EMA · What's New

    感染病学:Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 64, Status: Authorised

    原文摘录:Comirnaty RSS Authorised This medicine is authorised for use in the European Union COVID-19 mRNA vaccine Medicine Human Authorised Rolling review Application under evaluation CHMP opinion European Commission decision Overview Comirnaty is a vaccine for pr … 5-containing Covid-19 mRNA vaccines in the Nordic countries - post-authorisation study A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU - post-authorisation study Real-world effectiveness of different COVID-19 vaccines in Spain: a cohort study based on public electronic health records (BIFAP) (effectiveness of COVID-19 vaccines in Spain) - post-authorisation study This page was last updated on 06/11/2026

  2. EMA · What's New

    感染病学:Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 34, Status: Authorised

    原文摘录:Entyvio RSS Authorised This medicine is authorised for use in the European Union vedolizumab Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Entyvio is a medicine used to treat adult patients with … 73 KB - PDF) First published: 21/03/2014 Last updated: 21/03/2014 View News on Entyvio Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021 17/12/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020 28/02/2020 European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014 10/07/2014 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 March 2014 21/03/2014 European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohn's disease 21/03/2014 More information on Entyvio EMEA-000645-PIP03-18 - paediatric investigation plan EMEA-000645-PIP01-09-M09 - paediatric investigation plan EMEA-000645-PIP04-20-M02 - paediatric investigation plan Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025 - post-authorisation study Vedolizumab-5001: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry - post-authorisation study Vedolizumab-5056: Clinical Effectiveness of Vedolizumab Used in Frames of Drug Program for Crohn’s Disease Treatment in Poland – Prospective, Observational Study Considering Fatigue and Other Patient-reported-outcomes (PROs) (POLONEZ II) - post-authorisation study Comparative Effectiveness of Tofacitinib Versus Ustekinumab and Vedolizumab among Ulcerative Colitis Patients With Prior Anti- Tumor Necrosis Factor (TNF) Failure - post-authorisation study Topics Medicines This page was last updated on 06/11/2026

  3. PubMed · Clinical Microbiology Reviews

    综述:新型β-内酰胺类及β-内酰胺/β-内酰胺酶抑制剂复方对抗碳青霉烯酶产酶肠杆菌目(CPE)的微生物学进展

    Clinical Microbiology Reviews发表综述,系统梳理针对碳青霉烯酶产酶肠杆菌目(CPE,涉及KPC、OXA-48-like、NDM、VIM、IMP等A、B、D类酶)的新型β-内酰胺类及β-内酰胺/β-内酰胺酶抑制剂复方。内容涵盖头孢地尔及含青霉烷砜、重氮双环辛烷和环状硼酸类抑制剂复方的结构与机制特征、体外抗菌活性及新发耐药机制,以指导临床定位和新药开发。

  4. PubMed · International Journal of Biological Macromolecules

    感染病学:Valorization of pomegranate peel into active packaging films: Pectin/gelatin matrices empowered by residue-derived carbon dots for blueberry shelf-life extension.

    原文摘录:The increasing demand for sustainable food packaging technologies has stimulated the development of biomass-derived active materials capable of simultaneously reducing agricultural waste and extending food shelf life.

  5. PubMed · Cell Reports

    Cell Reports发表临床前研究:编码嵌合与马赛克血凝素的自扩增mRNA疫苗对系统发育多样的甲型流感病毒产生广谱免疫

    临床前研究显示,编码嵌合(cHA)与马赛克(mHA)血凝素的自扩增mRNA(samRNA)疫苗经初免-加强免疫后,组1疫苗(cH8/1-cH5/1)诱导广谱交叉反应抗体,对覆盖数十年抗原漂移的多种H1N1株完全保护;组2疫苗(cH4/3-cH15/3、mH10/3-mH14/3)对多种H3N2株及异亚型H7N9攻击提供类似广度,cHA samRNA跨组保护更优。

  6. PubMed · PLoS neglected tropical diseases

    美国佛罗里达州汉森病(麻风)1996–2025年流行趋势分析:年发病率从0.01升至0.15/10万,30年增长15倍

    研究者利用公开数据分析美国佛罗里达州1996–2025年汉森病(麻风)流行趋势,期间共报告359例确诊病例,年发病率从0.01/10万升至0.15/10万,增长15倍。2023年美国共报告225例新病例,佛州为主要报告州之一;Brevard县以113例成为确诊病例热点,在已知感染来源的病例中本地获得性感染占比最大。

  7. PubMed · PLoS neglected tropical diseases

    观点文章:麻风多药物治疗不能消除眼部残疾风险,呼吁建立治疗中评估与风险分层随访衔接路径

    观点文章指出,麻风联合化疗(MDT)虽可实现微生物学治愈,但不能逆转已建立的神经损伤,也不能消除未来眼部并发症风险;兔眼、角膜感觉减退、暴露性角膜病变、葡萄膜炎等可在诊断时、治疗中或治疗结束后长期出现。作者建议将治疗中眼部评估与治疗完成后的风险分层随访、明确转诊责任、支持性自我照护及视力结局常规记录相衔接,并整合入现有麻风、初级保健和眼科服务体系。

  8. PubMed · The Lancet Infectious Diseases

    Ganaplacide联合lumefantrine固体分散体治疗儿童非复杂性恶性疟的KALUMI开放标签多中心随机对照II期非劣效试验

    一项在布基纳法索、马里、科特迪瓦、加蓬和刚果(金)十家机构开展的开放标签、多中心、随机、适应性、II期非劣效试验(NCT04546633,已完成),评估ganaplacide 400 mg联合lumefantrine固体分散体治疗非复杂性恶性疟儿童(6个月至<18岁)的食物效应与非劣效性,对照artemether-lumefantrine。

11月5日周四
  1. PubMed · Journal of Applied Microbiology

    感染病学:A microfluidic model of bacterial keratitis to quantify the efficacy of anti-infective compounds under flow.

    原文摘录:AIMS: Bacterial infections of the cornea, also known as bacterial keratitis, are a major cause of blindness. The corneal surface is protected against infection by the flow of tear fluid, which displaces potential pathogens and debris. … These findings, obtained using two widely studied model strains, illustrate how microfluidic models of infection can offer valuable insights into how flow influences bacterial keratitis and guide the development of new treatments

  2. PubMed · Blood

    感染病学:The Pathogen Recognition Receptor RIG-I is Functional in Platelets and Limits Thrombotic Responses.

    原文摘录:Influenza is associated with increased thrombotic risk, and its viral RNA (vRNA) can be sensed by pattern-recognition receptor RIG-I, but the function of RIG-I in platelets remains unknown. … Our study is the first to demonstrate that platelets have a functionally active vRNA-sensing RIG-I receptor that finely tunes thrombotic risk and facilitates appropriate leukocyte transmigration during infection, through non-classical platelet activation

    关注理由:这篇感染病学资料可用于了解领域进展,研究设计、结果和局限性值得一起阅读。

  3. PubMed · Critical Care Medicine

    感染病学:Long-Term Mortality in Sepsis Survivors: A Population-Based Study During 15 Years.

    原文摘录:OBJECTIVES: To evaluate long-term mortality among sepsis survivors in Catalonia over a 15-year period and to identify factors associated with increased mortality within 2 years after hospital discharge. DESIGN: Retrospective population-based cohort study.

    关注理由:这篇感染病学队列研究资料适合了解长期变化,研究对象、随访方式和结局指标建议一起查看。

  4. PubMed · The Lancet Infectious Diseases

    病例报告:特立妥单抗(teclistamab)治疗骨髓瘤患者发生淋巴细胞脉络丛脑膜炎病毒脑膜脑炎,联合抗病毒治疗改善

    《The Lancet Infectious Diseases》报道英国一例复发多发性骨髓瘤患者在接受双特异性抗体teclistamab治疗后发生淋巴细胞脉络丛脑膜炎病毒(LCMV)脑膜脑炎,经脑脊液宏基因组二代测序确诊,并有家养啮齿类动物接触史。

11月4日周三
  1. PubMed · Science Translational Medicine

    VRC01抗体预防HIV-1感染随访至104周:敏感毒株获保护后出现耐药突破感染

    研究团队分析AMP两项平行试验至104周最终访视的HIV-1获得情况:静脉输注广谱中和抗体VRC01后,对VRC01高度敏感(IC80<阈限)的病毒感染被阻断,而随着体内VRC01浓度下降,在药物选择压力下 evolved 出更强耐药性的病毒以可检出的突破感染出现(VRC01组11例对安慰剂组1例)。结果提示单株抗体只能阻断敏感株,预防病毒逃逸与突破感染可能需要多种抗体联合。

  2. WHO · Official News OData

    感染病学:Progress against neglected tropical diseases requires sustained action

    原文摘录:WHO / Monika Mey Local health workers in Cambodia are trained in surveillance techniques, including stool examination using Kato-Katz, to detect schistosomiasis eggs, identify potential hotspots and support early detection and treatment. … int Related Global report on neglected tropical diseases 2026 Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030 WHO's work on neglected tropical diseases More WHO Global Neglected Tropical Diseases Programme

    关注理由:关于感染病学的这条内容有明确出处,主要发现和适用人群可在原文中继续核查。

  3. PubMed · The EMBO Journal

    感染病学:Tetraspanin CD81 restricts Ebola virus infection and is antagonized by glycoprotein GP and matrix protein VP40.

    原文摘录:Viruses manipulate host cell membranes to evade antiviral immunity, prevent superinfection, and optimize their replication and spread. … Our study provides insights into the roles of NF-κB signaling in Ebola virus replication and immunopathogenesis, and identifies tetraspanin CD81 as a potentially druggable Ebola virus-inhibitory host factor

11月3日周二
10月29日周四
  1. PubMed · AIDS

    常规医疗中来那卡韦(lenacapavir)用于HIV暴露前预防的早期患者报告结局与计划持续用药研究

    一项多中心研究评估了在常规医疗中开始每半年一次来那卡韦(lenacapavir, LEN)HIV暴露前预防(PrEP)者的早期患者报告结局。减少给药频率带来的便利是启用LEN的主要动机,尽管注射部位反应常见但多为轻度,总体满意度较高;持续性结节和疼痛是患者对未来继续用药的主要顾虑。研究提示需以患者为中心的咨询和实施策略来优化长效PrEP的长期坚持。

10月28日周三
10月23日周五
  1. PubMed · European Journal of Pharmacology

    感染病学:Pharmacodynamic evaluation of the novel vancomycin derivative LYSC98.

    原文摘录:LYSC98 is a novel synthetic derivative from chemical modification of vancomycin. In this study, the antibacterial efficacy of LYSC98 was systematically evaluated against multiple clinically significant pathogens using Minimal Inhibitory Concentration (MIC … These results indicate that, within the strains, doses and models tested, LYSC98 is active against the Gram-positive species examined and is more effective than vancomycin in selected infection models

10月22日周四
  1. PubMed · Journal of Medicinal Chemistry

    感染病学:Development of N-Hydroxyindole-2-Carboxamides as New Host-Targeted Broad-Spectrum Antiviral Agents Against Human Respiratory Viruses.

    原文摘录:Endoplasmic reticulum (ER) oxidoreductases are promising targets for host-targeted antiviral agents (HTAs) because of their essential role in protein folding, including the maturation of viral proteins. … This new class of HTAs provides promising leads for drug discovery targeting viral envelope protein maturation vulnerabilities and is suitable for developing new BSAs

10月16日周五
  1. PubMed · Biochimica et Biophysica Acta (BBA) - Biomembranes

    细胞内固体核磁共振研究噬菌体感染杀鲑气单胞菌引起的膜扰动

    一项体外/活菌固体核磁共振研究以氘代棕榈酸标记杀鲑气单胞菌亚种完整菌膜,比较A-layer阳性噬菌体敏感株AS-R3、A-layer阴性敏感株AS-R5与不敏感株BIM93在噬菌体SW69-9暴露后的膜序变化。敏感株膜序明显下降,AS-R5活力显著丧失,BIM93维持膜结构与活力,AS-R3呈膜扰动但裂解有限的中间表型,提示噬菌体诱导的膜扰动取决于噬菌体敏感性与细菌包膜结构。

  2. WHO · Disease Outbreak News OData

    感染病学:Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia

    原文摘录:Disease Outbreak News Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia 15 October 2026 See all DONs related to this event Situation at a glance Between 1 January and 5 October 2026, the Kingdom of Saudi Arabia reported eight laborato … int/emergencies/disease-outbreak-news/item/2026-DON618 See all DONs related to this event

10月10日周六
  1. WHO · Disease Outbreak News OData

    感染病学:Pneumonia of undetermined etiology - the Russian Federation

    原文摘录:Disease Outbreak News Pneumonia of undetermined etiology - Russian Federation 10 October 2026 See all DONs related to this event Situation at a glance On 2 October 2026, WHO became aware through media reports of the death of an employee of the Irkutsk Ant … item/2026-DON620 See all DONs related to this event

    关注理由:这条感染病学资料适合作为深入阅读入口,尤其要关注研究方法与结论是否匹配。

10月7日周三
9月1日周二